期刊文献+

自身抗原核点蛋白Sp100基因克隆和真核表达 被引量:1

Gene cloning and fusion expression of human autoantigen Sp100 in yeasts
暂未订购
导出
摘要 目的:克隆人核点蛋白自身抗原Sp100基因, 构建重组表达质粒,获得具有免疫学活性的纯化重组蛋白.方法:从人类肝脏cDNA文库中扩增出Sp100 的基因片段,克隆至PEGH表达载体进行诱导表达,并对表达产物进行十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和蛋白质印迹法(Western blot)鉴定.结果:经重组质粒测序结果证实,Sp100目的基因已正确插入真核表达载体中,基因序列正确,符合表达框架;SDS-PAGE检测表达产物分别在53 ku,55 ku,52 ku,37 ku,42 ku,47 ku 处有一明显的蛋白表达条带,Western blot分析表明重组蛋白2,3,5,6具有人sp100抗原反应性.结论:本研究成功克隆人核点蛋白自身抗原 Sp100基因,并将其在酵母菌中成功表达. AIM: To clone and construct the plasmid containing human autoantigene Sp100 gene, and then to identify the immunoreactivity of the purified recombinant protein. METHODS: The Sp100 gene was amplified from human liver cDNA library, and then was cloned into PEGH vector to induce the Sp100 expression. The obtained products were identified and analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and Western blot. RESULTS: The sequence of Sp100 autoantigene gene was confirmed to be the same as the sequence reported in GenBank. The fusion proteins were found at 53-, 55-, 52-, 37-, 42-, and 47-ku strip on SDS-PAGE gel. Western blot analysis showed that the fusion protein with 55,52, 42 and 47 ku had the same immunoreacfivity as human Spl00 autoantigene. CONCLUSION: Human plasmid containing Sp100 gene is successfully cloned and expressed in yeast Y258.
出处 《世界华人消化杂志》 CAS 北大核心 2006年第8期758-762,共5页 World Chinese Journal of Digestology
基金 国家自然科学基金项目 No.30471617 国家高技术研究发展计划(863计划)重大专项基金资助项目 No.2002AARZ2011
关键词 原发性胆汁性肝硬化 核点蛋白Sp100基因 自身抗原 克隆 Primary biliary cirrhosis Nuclear dots Sp100 protein Autoantigen Cloning
  • 相关文献

参考文献3

二级参考文献36

  • 1Berg PA, Klein R. Anti-mitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig Dis 1992; 10:85-101.
  • 2Bunn CC, McMorrow M. Anti-M4 antibodies measured by a sulphite oxidase ELISA in patients with both anti-centromere and anti-M2 antibodies. Clin Exp Immunol 1995;102:131-136.
  • 3Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002; 97:999-1002.
  • 4Heathcote EJ. Management of Primary Biliary Cirrhosis.Hepatology 2000; 31:1005-1013.
  • 5Dickson ER, Grambsch PM, Fleming TR, Fisher LD,Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
  • 6Sakugawa H, Nakasone H, Nakayoshi T, Yamashiro T,Maeshiro T, Kobashigawa K, Kinjo F, Saito A, Zukeran H,Nakanuma Y, Ohba K. Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa, Japan. Hepatol Res 2003;26:330-336.
  • 7Flisiak R, Wiercinska-Drapalo A, Prokopowicz D. Antibodies against M2 antigen in differential diagnosis of primary biliary cirrhosis. Pol Merk Lek 2000; 8:373-375.
  • 8Reisman Y, van Dam GM, Gips CH, Lavelle SM, Euricterus PM. Survival probabilities of Pugh-Child-PBC classified patients in the euricterus primary biliary cirrhosis population,based on the Mayo clinic prognostic model. Euricterus Project Management Group. Hepatogastroenterology 1997; 44: 982-989.
  • 9Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years. Gastroenterology 2002; 123:1044-1051.
  • 10Krzeski P, Zych W, Kraszewska E, Milewski B, Butruk E,Habior A. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 1999;30:865-869.

共引文献24

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部